Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study

  1. Chari, A.
  2. Rodriguez-Otero, P.
  3. McCarthy, H.
  4. Suzuki, K.
  5. Hungria, V.
  6. Sureda Balari, A.
  7. Perrot, A.
  8. Hulin, C.
  9. Magen, H.
  10. Iida, S.
  11. Maisnar, V.
  12. Karlin, L.
  13. Pour, L.
  14. Parasrampuria, D.A.
  15. Masterson, T.
  16. Kosh, M.
  17. Yang, S.
  18. Delioukina, M.
  19. Qi, M.
  20. Carson, R.
  21. Touzeau, C.
Aldizkaria:
British Journal of Haematology

ISSN: 1365-2141,  0007-1048

Argitalpen urtea: 2021

Alea: 192

Zenbakia: 5

Orrialdeak: 869-878

Mota: Artikulua

DOI: 10.1111/BJH.16980 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus